Exscalate: supercomputing and artificial intelligence for drug discovery and design

Despite tremendous technological advances in drug discovery and medicinal chemistry, the failure rate of new molecular entities remains extremely high, and drug development costly and slow. Dompé, a global biopharmaceutical company with a 130-year legacy of medical innovation, is here to solve the problem. Leveraging strong drug development capabilities and more than 20 years of experience, Dompé has developed the most advanced intelligent supercomputing platform for drug testing, and the largest enumerated chemical library in the world for preclinical and candidate identification, enabling faster, more efficient and inexpensive drug discovery. "Our virtual screening platform, Exscalate, leverages high-performance computing, big data and artificial intelligence (AI) to perform in silico drug testing and design," explained Andrea R. Beccari, head of discovery platform senior director. "The platform not only has unprecedented speed, quality and scalability, but is also open to the scientific community to drive innovation."